Aug 07, 2026
2026 Mid-Year China Access Outlook Strategic Debrief
Rebalancing Innovation Access Under Tighter Constraints
As of mid-2026, recent and ongoing developments point to a more deliberate recalibration
Kelly Ke
Jun 17, 2026
China’s C-List and Beyond: Group Insurance, Provider Uptake, and Commercial Payment Strategies
A practical implementation deep-dive with Professor Wanyan on China’s C-List and broader commercial payment landscape — covering group health insurance, provider uptake, cross-stakeholder bottlenecks, orphan therapy coverage, TPAs, and scalable payment strategy.
Jun 10, 2026
China’s C-List in Practice: Early Huiminbao Integration Signals
A practical discussion with Professor Wanyan on Huiminbao benefit design changes, regional adoption differences, local negotiation dynamics, and what early implementation may signal for broader commercial insurance integration.
Jun 03, 2026
China’s C-List: Behind-the-Scenes Negotiation Dynamics
A practical implementation deep-dive into China’s 2025 C-List negotiation process with Professor Wanyan — covering insurer participation, NHSA’s role, selection criteria, pricing negotiation, and future commercial insurance formulary trends.
May 15, 2026
China’s 2026 Dual-List Draft Workplan: Earlier Innovation Access, Tighter Lifecycle Pricing Discipline
China’s 2026 NRDL draft workplan signals a more integrated, lifecycle-oriented reimbursement framework: earlier access for innovative therapies, closer regulatory–reimbursement alignment anchored in RWE, and tighter pricing discipline for mature and me-too products.
Apr 09, 2026
China’s Healthcare System Is Reorganizing: What It Means for Manufacturers
As China’s healthcare system reorganizes, evolving care pathways and payment dynamics are reshaping how access is secured and how value is realized.
Mar 12, 2026
RWE and the Quiet Rewiring of China’s Reimbursement System
Five recent policy releases show how real-world evidence is quietly reshaping pricing, reimbursement, and clinical adoption for both innovative and established medicines in China.
Feb 12, 2026
Three Shifts Reshaping China’s Drug Payment System: Implications for Global Pharma
China’s drug payment system is shifting from isolated policy levers toward an environment defined by their interaction. Recent signals are beginning to link pricing, launch timing, and multi-payer access in ways that materially change how global pharma approaches China.
Jan 14, 2026
From Reference Tool to Operating Model: A Roadmap for China’s C-List
China’s C-List establishes a national reference for innovative drugs outside the NRDL—but not yet a payment system. Its impact will hinge on whether insurers and regulators can turn policy intent into a workable, risk-sustainable commercial coverage model.
Dec 15, 2025
China Establishes Market-Price Database, Reshaping Global Pricing Signals
China’s new drug price database marks a subtle but important shift in price governance—separating how market prices are recorded from how reimbursement is negotiated. The change reshapes pricing signals in ways that matter for both domestic innovators and multinational firms.